Section
A phase 3 trial demonstrates prademagene zamikeracel significantly accelerates healing and reduces pain in large, chronic RDEB wounds, offering a promising gene therapy with a favorable safety profile.
Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.
A randomized trial finds that subcutaneous cockroach immunotherapy effectively downregulates dominant T-cell responses in pediatric asthma, independent of allergen abundance in the therapeutic extract.
A randomized trial shows that a smartphone-based asthma self-management program improves symptom control in adults, though its effectiveness is attenuated in African American participants.
